Brian Yang
Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.
Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.
Latest From Brian Yang
Siemens Healthineers Gets Varian In $16.4Bn Deal To Enter Cancer Treatment Market
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.
Siemens Healthineers Gets Varian In $16.4Bn Deal To Enter Cancer Treatment Market
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.
Chi-Med Extends Oncology Commercial Reach To Realize China Potential
Chi-Med has revised its commercial rights agreement in China for Elunate (fruquintinib) with Lilly to seize China’s rapid growth trajectory, CEO Christian Hogg tells Scrip.
China’s Coronavirus Vaccine Ambition Hampered By Lack Of Guidance On Overseas Clinical Data
As two Chinese-developed vaccines against COVID-19 enter the final stage of testing in Latin America and the Middle East, a lack of guidance on using data obtained outside China could potentially pose challenges to regulatory approvals at home.
China Advances Two Coronavirus Vaccines Into Phase III
Chinese state-owned company Sinopharm has started a Phase III coronavirus vaccine study in Abu Dhabi, while another Chinese firm, Sinovac, has commenced its trial with partner Butantan in Brazil. Meanwhile, regulators in Beijing have started an audit process to ensure regulatory compliance.
Asia Deal Watch: Promethera Calls On Hao Tian For Asian JV To Advance Its Liver Candidates
Plus recent deals involving BeiGene, Assembly Biosciences, Piramal, Medivant, Revitope, Junshi, JW Therapeutics, Eureka, Acepodia, Chiesi, Bayer, NewG Lab, AnHeart